MAO-B-IN-19
MAO-B-IN-19 is a selective MAO-B inhibitor with an IC50 of 0.67 μM. MAO-B-IN-19 shows neuroprotective and anti-inflammatory properties.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 152897-41-1
- Formule: C15H11FO2
- Masse moléculaire:242.25
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
MAO-B 0.67 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
20.5 μM
Compound: 3m
|
Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 23771043] |
| HeLa | IC50 |
22.6 μM
Compound: 1e, 1PF
|
Cytotoxicity against human HeLa cells assessed as decrease in cell survival after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as decrease in cell survival after 72 hrs by MTT assay
|
[PMID: 23501110] |
| K562 | IC50 |
17.9 μM
Compound: 1e, 1PF
|
Cytotoxicity against human K562 cells assessed as decrease in cell survival after 72 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as decrease in cell survival after 72 hrs by MTT assay
|
[PMID: 23501110] |
| MCF7 | IC50 |
26 μM
Compound: 1e, 1PF
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell survival after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as decrease in cell survival after 72 hrs by MTT assay
|
[PMID: 23501110] |
| PC-3 | IC50 |
30.4 μM
Compound: 1e, 1PF
|
Cytotoxicity against human PC3 cells assessed as decrease in cell survival after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as decrease in cell survival after 72 hrs by MTT assay
|
[PMID: 23501110] |
| RAW264.7 | IC50 |
>10 μM
Compound: 12
|
Inhibition of LPS-stimulated ROS production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation for 24 hrs measured after 30 mins by CMH2DCFDA probe-based fluorescence assay
Inhibition of LPS-stimulated ROS production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation for 24 hrs measured after 30 mins by CMH2DCFDA probe-based fluorescence assay
|
[PMID: 28159411] |
In Vitro
MAO-B-IN-19 (compound 3f) significantly inhibits self-induced Aβ1-42 aggregation and shows remarkable neuroprotective effects on Aβ25-35-induced PC12 cell injury. MAO-B-IN-19 is a selective metal chelator and could inhibit Cu2+-induced Aβ1-42 aggregation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 152897-41-1
-
Masse moléculaire 242.25
-
Formule C15H11FO2
-
SMILES
C1=CC=C(C(=C1)C(=O)/C=C/C2=CC=C(C=C2)F)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)